Coronavirus Disease 2019 mRNA Vaccination Appears Safe in Pediatric Patients With Hypersensitivity to Polyethylene Glycolated Escherichia Coli L-asparaginase-Reference-Cited by-同舟云学术

Coronavirus Disease 2019 mRNA Vaccination Appears Safe in Pediatric Patients With Hypersensitivity to Polyethylene Glycolated Escherichia Coli L-asparaginase

Published:2024-01-05 Issue: Volume: Page:
ISSN:1077-4114
Container-title:Journal of Pediatric Hematology/Oncology
language:en
Short-container-title:

Author:

Wolfset Nicole¹,Pashmineh Azar Amir Reza²,Phillips Charles A.²³,Stein Madison²,Rheingold Susan R.²,Heimall Jennifer¹,Elgarten Caitlin W.²

Affiliation:

1. Division of Allergy and Immunology, Children’s Hospital of Philadelphia

2. Division of Oncology, Children’s Hospital of Philadelphia

3. Department of Biomedical and Health Informatics, Children’s Hospital of Philadelphia, PA, Philadelphia

Abstract

Polyethylene glycol–asparaginase (PEGAsp) is an established component of acute leukemia therapy. Hypersensitivity reactions to PEGAsp occur in 10% to 15% of patients, with polyethylene glycol suggested as the antigenic culprit. As coronavirus disease 2019 (COVID-19) mRNA vaccines contain polyethylene glycol, the safety of administration of these vaccines to patients with prior PEGAsp hypersensitivity has been questioned. Between December 21, 2020 and March 3, 2022, 66 patients with acute leukemia and PEGAsp allergy received COVID-19 vaccination. No patients (0/66 0%, 95% CI: 0%-5.4%) experienced an allergic reaction to the vaccine. COVID-19 mRNA vaccination appears to be safe in pediatric and young adult patients with acute lymphoblastic leukemia with PEGAsp allergy.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference14 articles.

1. Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia;Burke;Leuk Lymphoma,2017

2. Immediate-type hypersensitivity to polyethylene glycols: a review;Wenande;Clin Exp Allergy,2016

3. Allergy to COVID-19 vaccines: a current update;Cabanillas;Allergol Int,2021

4. Antibodies predict pegaspargase allergic reactions and failure of rechallenge;Liu;J Clin Oncol,2019

5. The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach;Greenhawt;J Allergy Clin Immunol Pract,2021